Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company’s highest priority market Discontinued the ex-U.S.-based PROACT 2 trial and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback